GSK's Blood Cancer Drug Review Extended As FDA Seeks More Data

Rueil-malmaison,,France,-,August,13,,2023:,Exterior,View,Of,The

The US Food and Drug Administration (FDA) on Wednesday extended the review period for the Biologics License Application (BLA) for GSK plc’s (NYSE:GSK) Blenrep combinations for relapsed or refractory multiple myeloma patients who have received at least one prior line of therapy.

• GSK is consolidating in the middle of its 52-week range. See the chart here.